Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.

MLA

Romero IL, et al. “Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity.” Obstetrics & Gynecology, vol. 119, no. 1, Jan. 2012, pp. 61–67. EBSCOhost, https://doi.org/10.1097/AOG.0b013e3182393ab3.

APA

Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel E, Romero, I. L., McCormick, A., McEwen, K. A., Park, S., Karrison, T., Yamada, S. D., Pannain, S., & Lengyel, E. (2012). Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstetrics & Gynecology, 119(1), 61–67. https://doi.org/10.1097/AOG.0b013e3182393ab3

Chicago

Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, et al. 2012. “Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity.” Obstetrics & Gynecology 119 (1): 61–67. doi:10.1097/AOG.0b013e3182393ab3.